Pbm ContractsMarch 11, 2026

PBM Rebates Explained: Where Manufacturer Money Actually Goes and How Much Reaches the Plan

The $400,000 Rebate Check That Wasn’t: Why the Math Rarely Adds Up

A 900-employee healthcare system CFO once called me, annoyed about a $64,000 "annual rebate" check their PBM had just sent. The HR team had been expecting something closer to $400,000 based on what pharma manufacturers reportedly pay in rebates for specialty drugs. The CFO’s question was blunt: “Where is the rest of the money?” If you’ve managed a pharmacy plan, you’ve probably gotten this same question from your own finance team after seeing a claims report or reading media headlines about “billions in rebates.” But the disconnect between what drugmakers pay and what lands back with employer plans is real, and it’s not just a one-time fluke.

Why does this gap exist? The answer lies in the byzantine rebate contract terms, how PBMs book revenue, and who else is getting paid along the way. I’ve seen employers with $1.5 million in annual specialty spend get just $120,000 in rebates, while their PBM’s own sales deck boasts “over 10% rebate share.” On a $1.5 million base, that’s $150,000, so where’s the difference? It’s in the details. If your CFO is asking for proof, you need to be more granular than just quoting “guaranteed rebates per script.”

How Rebates Actually Flow: From Pharma to PBM to Plan Sponsor

Drug manufacturers pay rebates as a way to secure favorable formulary placement. They want their brand drug preferred over a competitor, so they negotiate with PBMs like CVS Caremark, Express Scripts, or OptumRx. When your employees fill a prescription for an eligible drug, the manufacturer pays a rebate, often months later, to the PBM. But the money doesn’t go directly to your plan. First, the PBM subtracts fees, retains some “spread,” and sometimes shares only a portion of the total rebate, depending on your contract.

For most mid-market employers (200-5,000 employees), the contract typically entitles you to “pass-through” or “guaranteed” rebates. But even then, some PBMs quietly keep “admin” or “service” fees, or exclude certain types of rebates from the pass-through calculation. This is especially common with specialty drugs, think adalimumab (Humira, $34,000/year per patient), PCSK9 inhibitors (Repatha, Praluent), and GLP-1s like Ozempic and Wegovy.

For a 1,200-employee manufacturer with $2.1 million in annual pharmacy spend, specialty drugs made up 54% of their total claims cost, but less than 30% of their rebate dollars. Why? PBMs often classify some of the biggest specialty rebates as "non-shareable" or treat them as “network” incentives that don’t flow to the employer. That’s why your GDR (generic dispensing rate) or “average rebate guarantee” rarely tells the full story.

Retail vs. Specialty: Most retail brand drugs (think statins, inhalers, ADHD meds) pay rebates of $50-$200 per script. Specialty drugs may generate thousands, but PBMs may share only a fraction with the plan.
PBM Contract Terms: Some contracts guarantee a minimum rebate per brand script. Others guarantee a total dollar amount per year. The strictest contracts, especially with independent PBMs like Capital Rx or Navitus, may pass through 100% of received rebates, but only what is actually collected.
Timing: Rebates are paid quarterly, or even annually, months after the prescription is filled. If employees leave mid-year, you might not see their “share” in your check.

What the Big Three PBMs Actually Keep (and Why the Headlines Miss the Mark)

Media stories often cite “billions in rebates” as though all those dollars flow straight to employers and patients. That’s far from reality. The Big Three PBMs (CVS Caremark, Express Scripts/Cigna, OptumRx/UnitedHealth) control about 80% of the market and negotiate huge national rebate contracts. But their revenue disclosures show that much of what manufacturers pay stays with the PBM as “administrative fees,” “retained rebate,” or even as “price protection” on inflationary drugs.

As of 2023, publicly reported rebate retention rates for the Big Three range from about 5% to as much as 15%, depending on the line of business and the aggressiveness of their underwriting. What does that mean for your plan? If you’re receiving “100% pass-through rebates,” you’re getting 100% of a net figure after the PBM takes its contractual cut. Independent PBMs like Navitus and SmithRx are more transparent, often specifying “all manufacturer revenue” is returned, but even they have admin fees to cover claim processing and customer service.

Where things get really murky is “rebate optimization” programs, which some PBMs offer as bolt-ons or carve-outs. They’ll promise to maximize your “rebate yield” by changing formularies or steering volume to higher-rebate brands. In practice, I’ve seen these programs drive up plan costs because the highest-rebate drugs aren’t always the lowest net cost. For example, some GLP-1s may pay $200/month in rebates, but at a list price of $1,200/month, switching to a lower-net-cost alternative, even with lower rebates, can save more than chasing big manufacturer checks.

If you want to compare rebate performance across PBMs, don’t look only at the gross dollars. Look at your plan’s net cost per member per month (PMPM) after all rebates and admin fees. In a competitive PBM RFP, I’ve seen plan PMPMs vary from $117 to $138, even when “rebate pass-through” was identical on paper.

Red Flags and Real-World Strategies: Getting Beyond the Rebate Number

The biggest mistake I see is plans focusing almost entirely on “how much rebate are we getting?” rather than, “what is our net spend after everything?” It’s easy to get wowed by a $300,000 rebate line in a quarterly report, but if your total pharmacy spend is up 18% because of high-cost specialty drug utilization, you’re falling for the oldest PBM trick in the book.

Let’s look at rebates in context. Suppose you have a 600-employee tech company, spending $975,000 annually on pharmacy. Your PBM reports $110,000 in rebates for the year. But your specialty spend has climbed from 46% to 59% of total cost, driven by a dozen members on Ozempic, Humira, and new migraine injectables. If you could move four of those Humira patients to biosimilars (like Hadlima or Cyltezo, typically 40%-60% lower cost, though rebates are smaller), your plan could save $70,000 a year, even if your total rebates fall slightly.

Don’t chase the biggest rebate guarantee. Insist on transparency: require your PBM to disclose all sources of manufacturer revenue, including “admin” or “service” fees. Ask for a quarterly claim-level rebate reconciliation. If your PBM stalls or can’t provide it in detail, it’s a red flag. Some independent PBMs, like Capital Rx or RxBenefits, now provide near real-time rebate accrual reporting. If you’re seeing a disconnect between what you “should” get and what lands in your bank account, consider a rebate audit (you’ll want a pharmacy benefits consultant or, for legal contesting, an ERISA attorney).

It’s also worth reminding your executive team that rebates aren’t “free money.” They’re paid because the plan (and your employees) used more expensive brand drugs. The best-performing plans I’ve managed don’t have the highest rebate yield. They have the lowest net cost per member and the highest generic and biosimilar utilization. For more granular pricing benchmarks, including true net price by drug and class, use a resource like RxInfo.ai to reality-check your PBM’s math.

Finally, if your stop-loss broker or actuary is projecting savings based on “expected rebates,” make sure those numbers match your contract’s timing and definitions. Don’t let HR or finance get caught off guard with a much lower actual check. Rebates are a moving target, and only part of the pharmacy cost puzzle.

What You Should Ask Your PBM (and Yourself) About Rebates

Are all manufacturer payments, including admin/service fees, disclosed and passed through?
How are specialty drug rebates (especially for new launches) handled?
Do our net PMPM costs align with market benchmarks after all revenue and fees?
Can we see claim-level rebate data, or only summary reports?
What would our net plan savings be if we shifted utilization to generics, biosimilars, or lower-net-cost brands, even if rebates dropped?

Rebates remain one of the most misunderstood (and, frankly, overhyped) pieces of pharmacy benefit management. They’re not a panacea for rising drug costs. But with the right contract language, tough questions, and a focus on net cost rather than just headline savings, you can make sure more of that manufacturer money actually helps your plan, not just your PBM’s bottom line.